Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Clinical trial NCT04728893 · RECRUITING

Trial details

NCT number: NCT04728893
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hematologic Malignancies Waldenstroms Macroglobulinaemia Non-Hodgkins Lymphoma Chronic Lymphocytic Leukaemia

Start date: 2021-04-05
Primary completion: 2029-01-04
Enrollment: 490

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.